市场调查报告书
商品编码
1392144
数位病理学市场 - 按产品、应用、最终用途 - 全球预测,2023-2032 年Digital Pathology Market - By Product, Application, End-use - Global Forecast, 2023-2032 |
在产业领导者不断推出和创新的推动下,2023 年至 2032 年全球数位病理市场CAGR将达到 10.4%。先驱公司对成像技术、人工智慧驱动的分析和基于云端的解决方案进步的不懈追求重塑了病理学实践。例如,2023年11月,欧洲领先的解剖病理学资讯系统供应商Dedalus Group与以人工智慧驱动的癌症诊断而闻名的Ibex Medical Analytics合作,推出了由人工智慧驱动的先进数位病理学解决方案,使用于癌症诊断。此整合解决方案将 Ibex 的 Galen (TM) 平台与 Dedalus 的综合数位病理学解决方案相结合,为解剖病理学实验室数位化树立了开创性的基准。
尖端产品的推出提高了诊断准确性,简化了工作流程,并支援远端存取医疗资料,彻底改变了医疗保健服务。数位病理学市场需求的增加反映了该行业对技术突破的反应能力,强调了创新在提高诊断精度和改变全球病理学服务格局方面的关键作用。
数位病理学市场的总体份额根据产品、最终用途和地区进行分类。
从 2023 年到 2032 年,软体领域将经历重大发展。先进的数位病理学软体将彻底改变医疗诊断,提供精确性、可扩展性和远端可访问性。这些软体解决方案利用人工智慧、机器学习和影像分析来增强病理工作流程,从而实现更快、更准确的诊断。随着全球医疗机构的采用激增,数位病理学市场份额见证了对软体的需求不断增加,这些软体为病理学家提供了全面的工具,提高了效率并帮助复杂的疾病检测和治疗计划。
2023年至2032年,医院领域的数位病理市场规模将出现显着的CAGR。为了改善病患护理,医院越来越多地采用数位病理技术。这些创新简化了工作流程,提供对病理资料的远端访问,并增强了医疗保健专业人员之间的协作。数位病理工具使医院能够加快诊断速度、提高准确性并促进与现有医疗保健系统的无缝整合。人们对这些好处的日益认识推动了全球医疗机构对数位病理学市场需求的不断增长。
欧洲数位病理学产业从 2023 年到 2032 年将呈现出值得称讚的CAGR。欧洲国家正在采用数位病理学解决方案来提高诊断准确性、简化工作流程并改善患者护理。政府支持创新医疗技术的倡议以及远端存取病理资料的需求推动了这一激增。随着该地区日益强调精准医疗和医疗保健的进步,欧洲医疗机构对数位病理系统的需求持续稳定成长。
例如,2023 年 11 月,荷兰先驱公司飞利浦于 2017 年推出了 FDA 批准的用于初级诊断的数位病理切片扫描仪,成为数位病理领域的开拓者。根据 KLAS Research 最新题为「美国数位病理学 2023」绩效洞察的报告,飞利浦因其在美国境内外拥有「最广泛的初级诊断客户群之一」而被认可,这得益于其值得称讚的数字病理解决方案。
Global Digital Pathology Market will witness 10.4% CAGR between 2023 and 2032, propelled by continuous launches and innovations by industry leaders. The relentless pursuit of advancements in imaging technologies, AI-driven analysis, and cloud-based solutions by pioneering companies reshapes pathology practices. For instance, in November 2023, Dedalus Group, a leading provider of anatomic pathology information systems in Europe, in collaboration with Ibex Medical Analytics, known for AI-driven cancer diagnostics, introduced an advanced Digital Pathology Solution powered by AI for cancer diagnosis. This integrated solution, merging Ibex's Galen™ platform with comprehensive Digital Pathology Solution by Dedalus, sets a pioneering benchmark in anatomic pathology lab digitization.
Cutting-edge launches enhance diagnostic accuracy, streamline workflows, and enable remote access to medical data, revolutionizing healthcare delivery. This heightened digital pathology market demand reflects the industry's responsiveness to technological breakthroughs, emphasizing the pivotal role of innovation in elevating diagnostic precision and transforming the landscape of pathology services globally.
The overall Digital Pathology Market share is classified based on product, end-use, and region.
Software segment will undergo significant development from 2023 to 2032. Advanced digital pathology software revolutionizes medical diagnostics, offering precision, scalability, and remote accessibility. These software solutions leverage AI, machine learning, and image analysis to enhance pathology workflows, enabling faster and more accurate diagnoses. With a surge in adoption across healthcare facilities worldwide, the digital pathology market share witnesses increased demand for software that empowers pathologists with comprehensive tools, improving efficiency and aiding in complex disease detection and treatment planning.
Digital pathology market size from the hospitals segment will register a noteworthy CAGR from 2023 to 2032. With a focus on improving patient care, hospitals are increasingly adopting digital pathology technologies. These innovations streamline workflows, offer remote access to pathology data, and enhance collaboration among healthcare professionals. Digital pathology tools empower hospitals to expedite diagnoses, improve accuracy, and facilitate seamless integration with existing healthcare systems. The growing recognition of these benefits fuels the escalating digital pathology market demand among healthcare institutions globally.
Europe digital pathology industry will showcase a commendable CAGR from 2023 to 2032. European countries are embracing digital pathology solutions to enhance diagnostic accuracy, streamline workflows, and improve patient care. This surge is bolstered by government initiatives supporting innovative healthcare technologies and the need for remote access to pathology data. As the region increasingly emphasizes precision medicine and advancements in healthcare, the demand for digital pathology systems continues to grow steadily across European healthcare facilities.
For instance, in November 2023, Philips, the pioneering company from the Netherlands that debuted an FDA-approved digital pathology slide scanner for primary diagnostic use in 2017, stood as a trailblazer in the realm of digital pathology. According to the most recent KLAS Research report titled 'U.S. Digital Pathology 2023' Performance Insights, Philips was recognized for possessing "one of the most extensive customer bases for primary diagnosis," both within and beyond the borders of the United States, owing to its commendable digital pathology solutions.